Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15948774.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mometasone furoate nasal spray (MFNS; Nasonex, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis.
Medical subject headings
- Anti-Allergic Agents
- Pregnadienediols
- Rhinitis, Allergic, Perennial
- Rhinitis, Allergic, Seasonal